Paradigm Biocapital Advisors LP
Q4 2025 13F-HR Holdings
Net value change ($000)
+401,633
(11.4%)
New positions
8
Sold out positions
12
Turnover %
29.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| RVMD | 238,599 | 82.1% |
| OLMA | 122,089 | 183.6% |
| GMAB | 99,764 | 85.2% |
| CDTX | 75,739 | 82.3% |
| NUVL | 74,351 | 16.3% |
| EWTX | 62,240 | 62.2% |
| SRRK | 60,045 | 80.2% |
| ABVX | 58,353 | 43.9% |
| ORKA | 51,840 | NEW |
| PCVX | 51,371 | 37.7% |
Top Reduces (Value $000, Stocks/ETFs)
| Merus N.V. | -411,790 | -100.0% |
| AGIO | -107,316 | -100.0% |
| JANX | -71,371 | -100.0% |
| ALKERMES PLC | -51,580 | -100.0% |
| LENZ | -50,002 | -100.0% |
| PHVS | -45,796 | -100.0% |
| COGT | -45,326 | -100.0% |
| TNGX | -25,924 | -100.0% |
| AMLX | -25,821 | -100.0% |
| DYN | -24,022 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
182,895
(4.7% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|